PRKN and neoplasm: We have previously shown that EGFR and MMP1 act as key players in PM motility and EMT (epithelial to mesenchymal transition)‐like changes [26], and EPHA5 and PARK2 have been described to both drive and inhibit tumor cell migration [27, 28, 29, 30].